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Objectives. This study compared exercise and pharmacologic 
stress testing using arbutamine delivered by a closed-loop device 
for the detection of coronary artery disease. 
Background. Arbutamine, an agent designed to simulate exer- 
cise, has been developed in conjunction with a closed-loop delivery 
device that modulates the rate of administration on the basis of 
physiologic feedback. 
Methods. Two hundred ten patients (180 men, 30 women) with 
symptoms and angiographic evidence of coronary artery disease 
were studied. Ischemia was categorized in three ways: 1) the 
presence of angina; 2) the occurrence of >0.l-mV horizontal or 
downsloping ST segment depression or elevation at 60 ms after 
the J point; or 3) the presence of either condition 1 or 2. 
Results. In the 210 patients, the mean increase in heart rate 
and systolic blood pressure evoked by arbntamine and exercise 
was 51 and 53 beats/min (p = NS) and 36 and 44 mm Hg (p < 
0.0001), respectively. Arbutamine detected ischemia more often 
than exercise with each of the three ischemic end points. Sensi- 
tivity for detecting ischemia by either angina or ST segment 
change was 84% (95% confidence interval [CI] 79% to 89%) for 
arbutamine and 75% (95% CI 69% to 81%) for exercise testing 
(p = 0.014). For angina alone, sensitivity was 73% (95% CI 67% to 
79%) for arbutamine and 64% (95% CI 57% to 71%) for exercise 
(p = 0.026). For ST segment change alone, sensitivity was 47% 
(95% CI 40% to 54%) for arbutamine and 44% (95% CI 37% to 
51%) for exercise (p = 0.426). Cardiac events occurred in five 
patients (1.8%) within 24 h of the arbutamine test. 
Conclusions. In detecting documented coronary artery disease, 
the sensitivity of arbutamine testing was equal to that of exercise 
for the electrocardiographic end point of ST segment change 
alone. Arbutamine testing was significantly superior to exercise 
testing for either ST change or angina or for angina alone. 
(J Am Coil Cardiol 1995;26:1151- 8) 
Pharmacologic stress testing using either vasodilators oragents 
with inotropic and chronotropic effects is a technique that has 
grown rapidly (1). Dobutamine, designed for inotropic support 
of the failing heart and with relatively less chronotropic than 
inotropic effects, has been applied to stress testing. Arbu- 
tamine, the first agent specifically designed to simulate xer- 
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cise, is a mixed beta t- and beta2-adrenoceptor agonist with 
mild atfinity for alphat-adrenoceptors. It has a similar degree 
of inotropic and chronotropic activity but less peripheral 
vasodilating activity than isoproterenol and less inotropic 
activity than dobutamine (2). Arbutamine has been developed 
in conjunction with a closed-loop delivery device that uses the 
subject's heart rate response (heart rate feedback) to modulate 
the rate of administration f arbutamine within prespecified 
dose, heart rate and blood pressure limits (Appendix 1). 
Results from earlier pilot studies using electrocardiography 
and echocardiography suggest that arbutamine can produce 
myocardial ischemia under controlled circumstances in ani- 
mals (3) and in patients with coronary artery disease. The 
present multicenter t ial was designed to compare the sensi- 
tivity of arbutamine with that of standard exercise protocols for 
eliciting electrocardiographic (ECG) and clinical indicators of 
myocardial ischemia in patients with known or suspected 
coronary artery disease. The response to arbutamine in a 
cohort with a low risk of coronary artery disease was evaluated 
@1995 by the American College ~tt ('aldit~t~g) 0735-1097/95/$9.50 
0735-1097(95)00297-H 
1152 DENNIS ET AL. JACC Vol. 26, No. 5 
STRESS TESTING WITH ARBUTAMINE November 1, 1995:1151-8 
in a second, independent group of patients. The end points 
used to determine sensitivity were also validated in this group. 
Methods 
Patients. A total of 243 men and women without childbear- 
ing potential, over the age of legal consent, with symptoms or 
signs of coronary artery disease necessitating coronary angiog- 
raphy or with angiographic evidence of coronary artery disease 
obtained within 6 weeks before or after stress testing were 
enrolled for evaluation of sensitivity. 
Screening included history, and physical examination, labo- 
ratory studies and electrocardiography. Patients were excluded 
if they had rest ECG abnormalities, unstable angina within 6 
weeks, myocardial infarction within 30 days, a pacemaker, a 
history of significant arrhythmia, heart failure (New York 
Heart Association functional class III or IV), cardiomyopathy 
and states of secondary ventricular hypertrophy, uncontrolled 
hypertension, aortic aneurysm or dissection, hypokalemia or 
other significant disease. Prohibited medications included tri- 
cyclic antidepressant agents, class I antiarrhythmic agents and 
drugs interfering with catecholamine metabolism within 1 
week; beta-adrenergic blocking agents within 48 h; atropine 
within 24 h; digitalis within 2 weeks: and amiodarone or any 
investigational drug within 30 days. 
Arbutamine and exercise testing. All patients underwent 
both exercise testing and closed-loop administration f arbu- 
tamine in randomly assigned order with 20 h to 14 days 
between tests. The test order was unknown to investigators 
until screening qualification procedures had been completed. 
Exercise testing was carried out on a treadmill using Bruce (4) 
or Naughton (5) protocols or bicycle crgometry (an initial load 
of 25 W for 2 min, increasing by 25 W each 2 min). Three ECG 
leads were continuously monitored and displayed uring test- 
ing, and 12-lead ECG recordings were printed at regular 
intervals during testing. 
Arbutamine was administered intravenously in the supine 
position, in the arm not used for measuring blood pressure, 
using a computerized closed-loop delivery system. The maxi- 
mal rate of arbutamine infusion allowed by the system was 
0.8 ~g/kg body weight per rain, and the maximal total dose 
allowed was 10/~g/kg. Audible and visual alerts and alarms 
were activated in response to potential problems, such as rapid 
changes in heart rate or a paradoxic decrease in blood pres- 
sure, which has been observed occasionally in earlier studies 
using catecholamines (6,7). If the infusion was stopped by the 
delivery system, the investigator could restart he infusion if it 
was judged to be safe, except o exceed the maximal total dose. 
The selected rate of heart rate increase was 8 beats/rain per 
min, and the maximal heart rate selected was (220 - age) × 
0.85 beats/min. Arbutamine testing was discontinued if heart 
rate saturation occurred (failure of heart rate to continue to 
increase despite increasing doses of arbutamine). 
Low risk cohort. A separate group of 64 patients was also 
evaluated, using the same closed-loop system, in a multicenter 
study designed to evaluate the responsc to arbutamine in a 
cohort with a low risk of coronary artery disease. These 
patients were referred for evaluation of possible coronary 
artery disease and either had atypical chest pain or were 
asymptomatic with significant risk factors for coronary artery 
disease. In addition, they had negative xercise treadmill test 
results within 8 weeks of the study or during the screening visit 
for the study, with an exercise treadmill nomogram score 
indicating a ->98% 5-year survival rate (8). 
Electrocardiographic and hemodynamic variables. In both 
studies, symptom-limited exercise or arbutamine stress tests 
were continued to horizontal or downsloping ST segment 
depression or elevation of 0.2 mV at the J point unless the 
maximal heart rate or intolerable angina, fatigue or other 
adverse events occurred. The maximal heart rate for arbu- 
tamine was limited by the device to (220 - age) x 0.85 
beats/min. For exercise, the maximal heart rate was at least 
(220 - age) x 0.85 beats/rain. The ECG and heart rate were 
continuously monitored, and heart rate was recorded intermit- 
tently during stress (arbutamine every 5 s, exercise very 2 or 
3 min). Blood pressure was recorded intermittently during 
stress (arbutamine each 2 min, exercise ach 2 or 3 min). After 
stress, heart rate and blood pressure were recorded at longer 
intervals for 30 min or until heart rate returned to within 20 
beats/min of baseline, whichever was longer. 
The target of 0.2-mV ST segment change was to ensure that 
0.1 mV of ST segment change would be present, were it to 
occur, when ECG tracings were subsequently assessed by the 
central investigational site. Ischemia was categorized after 
testing in three ways: 1) the presence of angina; 2) the 
occurrence of ->0.1-mV horizontal or downsloping ST segment 
depression or elevation at 60 ms after the J point; or 3) the 
presence of either condition. 
Coronary angiography. Coronary angiography was per- 
formed according to standard clinical practice at each investi- 
gational site. Coronary angiograms were analyzed at a central 
core facility by experienced observers who had no knowledge 
of the clinical or ECG data. Coronary artery dimensions were 
determined with the computer-based Quantitative Coronary 
Angiography System (9). The boundaries of a selected coro- 
nary artery segment were digitized and magnified by the Image 
Comm System (Image Comm, Inc.). The diameter of the 
coronary catheter was used for size calibration: mean diameter 
(pixels) versus known size (mm). The analysis oftware iden- 
tified the coronary artery borders in the optimal cineangio- 
graphic view using a double-differentiated approximation a d 
interactive operator interpolation. The proximal and distal 
ends, point of maximal stenosis and normal segment as the 
reference region were identified, and the maximal percent 
diameter stenosis was calculated. A significant coronary lesion 
was defined as ->50% stenosis. The records of all ECGs and 
angiograms for arbutamine and exercise tests were analyzed 
and interpreted by central investigational sites. 
Statistical analysis. Results are presented as mean value _+ 
SD or number (percent) of patients. All statistical tests to 
compare arbutamine and exercise tests were performed for 
patients with both test results at the 0.05 significance l vel. 
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Table 1. Reasons for Exclusion of Randomized Patients 
Failed to have angiogram 
Rest ECG abnormalities 
Received igitalis or beta-blockers 
Cardiac event during study* 
Improper administration f study drug 
Withdrew before both arbutamine and exercise tests 










*Occurred between first and second stress test, and second test not carried 
out: ventricular fibrillation (n = 2), coronary angiogram (n = 1), myocardial 
infarction (n = 1), unstable angina (n = 1), vasovagal syncope (n = 1); patients 
with these events were included in safew results. ECG = electrocardiographic. 
Tests for unequal carryover effects were set at the 0.10 level. 
Maximal changes in hemodynamic variables from baseline 
were compared between the two stress tests using a repeated- 
measures analysis of variance or a rank-transformed analysis of 
variance for two-period crossover data. Point and 95% confi- 
dence binomial interval estimates for sensitivity of the diagno- 
sis of ischemia (ST segment change or angina or either 
condition) were provided for each stress test, and the sensitiv- 
ities compared using the Fisher exact test or a continuity- 
corrected chi-square test for crossover data (10). The study was 
approved by the Institutional Review Board of each center, 
and written informed consent was provided by each patient. 
Resu l ts  
Patients. Of the 243 randomized patients, 33 were ex- 
cluded because of protocol violations, the most significant of 
which included failure to have an angiogram, rest ECG 
abnormalities, prohibited rugs and election to withdraw be- 
fore testing (Table 1). The demographics ofthe remaining 210 
patients are shown in Table 2. 
Nineteen of the 210 patients were subsequently found not 
to have a coronary artery stenosis ->50%, although all had 
clinical or angiographic evidence of coronary artery disease. 
The distribution of coronary disease-related vents is shown in 
Table 3. Fifteen of the 19 patients with <50% coronary 
stenosis had either prior myocardial infarction, coronary by- 
pass surgery, coronary angioplasty or typical angina. Four 
patients lacked any of these concomitants but had atypical 
Table 2. Demographic Data for 210 Patients 
No. (~) of 
Patients 
Gender 
Male 180 (86%) 
Female 30 (14~) 
Race 
Asian 5 (2%) 
Black 4 (2%) 
White 200 (95%) 
Other l (1%) 
Mean (-+SD) age (yr) 58.4 + 9.5 
Table 3. Evidence of Coronary Artery Disease 
No. of Patients 
Stenosis Stenosis 
History, _>5(1% <50% 
M1 75 3 
PTCA 7 3 
CABG 7 0 
MI and CABG 11 1 
M1 and PTCA 9 0 
CABG and PTCA 1 0 
MI, CABG and PTCA 4 0 
Typical angina 72 8 
None of the above 5 4 
Total 191 19 
CABG coronary artery bypass surgery,; MI = myocardial infarction; 
PTCA = percutaneous transluminal coronary angioplasty. 
angina necessitating coronary angiography. Three of those 
four patients had no sign of ischemia with either arbutamine or
exercise testing, and one had only ST segment depression 
during the arbutamine t st. The remaining 191 patients had 
one-, two- or three-vessel disease in similar numbers. 
Hemodynamic variables. Quantitative hemodynamic 
changes resulting from arbutamine and exercise testing were 
relatively similar (Table 4). There were modest differences in 
mean baseline heart rate and systolic blood pressure appar- 
ently related to the supine and standing positions of the 
arbutarnine and exercise tests: heart rate 71 versus 82 beats/ 
rain and blood pressure 139/83 versus 134/81 mm Hg, respec- 
tively. The mean increase in heart rate and systolic blood 
pressure voked by arbutamine and exercise was 51 versus 53 
beats/rnin (p = NS) and 36 versus 44 mm Hg (p < 0.0001), 
respectively. The maximal rate-pressure product (Systolic 
blood pressure × Heart rate) evoked was higher with exercise 
than with arbutamine: 237 versus 195 beats min-a.mm 
Hg.10 -2, respectively (p = 0.0001). 
There were differences in the temporal occurrence of 
hemodynamic changes with arbutamine and exercise (Table 4). 
Heart rate and systolic and diastolic blood pressures tracked 
together with exercise, with time to maximal change relatively 
similar at 6.7, 6.7 and 8.3 rain, respectively. With arbutamine, 
heart rate and systolic blood pressure tracked upward together, 
but diastolic blood pressure initially decreased and remained 
low through the majority of the arbutamine infusion. Thus, 
time to maximal heart rate and systolic blood pressure was 12.9 
and 13.6 rain, respectively, but time to maximal diastolic blood 
pressure was 21.9 min. Maximal rate-pressure product with 
arbutamine coincided with the nadir of the diastolic blood 
pressure. The median time for a 50% reduction in heart rate 
after termination ofthe arbutamine infusion was 12.5 rain, and 
after termination ofexercise, the comparable time was 2.0 rain. 
Sensitivity for detection of ischemia and extent of coronary 
artery disease. The distribution of patients by extent of coro- 
nary artery disease and the corresponding number of patients 
showing each of the ischemic end points is shown in Table 5. 
Sensitivity for detection of ischemia in patients with no vessel 
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Table 4. Hemodynamic Changes With Arbutamine and Exercise in Patients in the Sensitivity Group 
and With Arbutamine in Patients in the Low Risk Group 
Sensitivity Group (n = 198) 
Low Risk Group 
Arbutamine Exercise (arbutamine, n = 57) 
HR (beats/min) 
Baseline 70.9 _+ 12.0 
Maximal 121.9 _+ 14.2 
Maximal - baseline 51.0 _* 14.0 
SBP (ram Hg) 
Baseline 138.9 _+ 17.7 
Maximal 174.5 _+ 20.8 
Maximal - baseline 35.7 _+ 14.9 
DBP (mm Hg) 
Baseline 82.8 _+ 10.1 
Maximal 94.6 _+ 11.4 
Maximal - baseline 12.0 _+ 9.4 
BP (ram Hg) 
Baseline 101.5 _* 11.2 
Maximal 121.2 _+ 12.9 
Maximal - baseline 19.8 _+ 9.4 
Maximal rate-pressure product 19,516 _+ 3,532 
(beats rain t.mm Hg) 
Time to 
Maximal HR (min) 12.9 _+ 5.5 
Maximal SBP (min) 13.6 _+ 7.5 
Maximal DBP (min) 21.9 _+ 15.0 
Maximal rate-pressure product 12.9 _+ 5.2 
(beats min- l.mm Hg) 
81.8 --- 14.1" 68.1 +_ 11.3 
134.7 _+ 17.9 129.1 -+ 11.4 
53.7 -+ 17.6' 61.1 _+ 11.2 
134.3 -+ 18.6 122.0 _+ 14.7 
177.6 -+ 23.2 162.2 -- 16.0 
44.0 + 18.91 40.2 _+ 13.9 
81.2 -+ 10.5 
90.0 -+ 14.5 
9.1 -+ 12.1 
98.8 _+ 11.7 
119.2 + 15.4 
20.3 + 11.7 
23,729 --- 5,412 
6.7 -+ 2.8 
6.7 -+ 3.8 
8.3 -+ 8.2 
6.6 -+ 2.8 
20,939 _+ 2,679 
"196 observations, tP < 0.0001, exercise versus arbutamine in sensitivity group. BP = blood pressure; DBP = 
diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure. 
---50% stenotic or with one, two or three or more vessels 
involved is summarized in Table 5. With arbutamine or 
exercise and for each ischemic end point, there is a generally 
progressive increase in sensitivity with increasing severity of 
disease. Using the combination of either ST segment change or 
angina for the diagnosis (i.e., either one could be present), 
sensitivity for two- and three-vessel disease approximates 90% 
with arbutamine versus 82% with exercise. Overall, arbutamine 
detected ischemia more often than exercise with each of the 
three ischemic end points. Overall sensitivity for detecting 
ischemia by either angina or ST segment change was 84% 
(95% confidence interval [CI] 79% to 89%) for arbutamine 
and 75% (95% CI 69% to 81%) for exercise testing (p = 
0.014). For angina alone, sensitivity was 73% (95% CI 67% to 
79%) for arbutamine and 64% (95% CI 57% to 71%) for 
exercise (p = 0.026). For ST segment change alone, sensitivity 
was 47% (95% C140% to 54%) for arbutamine and 44% (95% 
CI 37% to 51%) for exercise (p = 0.426). 
Table 5. Percent Sensitivity, for Identification of Ischemia and Distribution of Patients by Extent of Coronary Artery Disease 
Extent of Angina ST ->0.1 mV Angina or ST ->0.1 mV 
Coronary 
Artery No. of Arbutamine Exercise Arbutamine Exercise Arbutamine Exercise 
Disease Pts [% (no. of pts)] [% (no. of pts)] [% (no. of pts)] [% (no. of pts)] [% (no. of pts)] [% (no. of pts)] 
Stenosis 
<50% 19 52 (10) 42 (8) 26 (5) 16 (3) 63 (12) 53 (10) 




1 61 64 (39) 59 (36) 31 (19) 33 (20) 79 (48) 67 (41) 
2 65 78 (51) 75 (49) 49 (32) 48 (31) 91 (59) 83 (54) 
->3 65 83 (54) 65 (42) 66 (43) 58 (38) 89 (58) 82 (53) 
Overall 210 73 (154) 64 (135)* 47 (99) 44 (92)t 84 (177) 75 (158)~ 
total 
*p = 0.026, tp = 0.426 (not significant), ~p = 0.014, for arbutamine more sensitive than exercise overall. Pts (pts) = patients. 
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Table 6. Agreement of Arbutamine and Exercise for Diagnosis of Ischemia by Angina or ST 
Segment Change 
Agreement Between Arb and Ex Disagreement Between Arb and Ex 
lschemia No Ischemia Total Arb Yes/Ex No Ex Yes/Arb No Total 
Stenosis 
-<50% 8 5 13 4 2 6 
->50% 137 15 152 28 11 39 
No. of diseased vessels 
1 36 8 44 12 5 17 
2 51 3 54 8 3 11 
->3 50 4 54 8 3 11 
Overall total 145 20 165 32 13 45 
Data presented are number of diseased vessels. Arb = arbutamine; Ex = exercise. 
Arbutamine and exercise were concordant in detecting 
ischemia on the basis of angina or ST segment change or either 
end point in 75%, 77% and 79% of patients, respectively. 
When arbutamine and exercise lacked agreement, arbutamine 
made the ischemic diagnosis more frequently than exercise 
testing in each category: angina alone 36 versus 17 patients; ST 
segment change alone 28 versus 21 patients; and either angina 
or ST segment change 32 versus 13 patients. Agreement of 
arbutamine and exercise testing in the diagnosis of ischemia by 
either angina or ST segment change is shown by number of 
diseased vessels in Table 6. 
Because a prior history of myocardial infarction, bypass 
surgery or balloon angioplasty could inject a bias into the 
sensitivity results, a separate analysis of sensitivity was carried 
out in those 89 patients without such a prior history. In this 
subgroup of patients, sensitivity was virtually the same as in the 
overall group. The overall sensitivity for detecting ischemia by 
angina or ST change was 84% for arbutamine and 74% for 
exercise testing. For angina alone, sensitivity was 73% for 
arbutamine and 64% for exercise. For ST segment change alone, 
sensitivity was 45% for arbutamine and 43% for exercise. 
Of the 64 patients in the low risk group, 63 received 
arbutamine. Four of these patients had screening evidence of 
prior myocardial infarction (three with Q waves on the ECG, 
and one with an echocardiographic wall motion abnormality) 
and were censored from analysis. The demographics and 
arbutamine t st results of the remaining 59 patients are shown 
in Table 7. Twelve patients had ST segment changes, but none 
had angina during arbutamine. Thus, patients at low risk for 
coronary artery disease had a 20% rate of ST segment devia- 
tion but no symptoms uggestive of angina with arbutamine 
testing. 
Five of the 285 patients (1.8%) (22 patients excluded from 
the sensitivity group never eceived arbutamine) who received 
arbutamine among the two groups experienced a significant 
cardiac event within 24 h of arbutamine administration. None 
was in the low risk group. The events included ventricular 
tachycardia/fibrillation during recovery terminated by a single 
direct current shock; prolonged chest pain walking uphill 1 to 
2 h after testing; an inferior wall myocardial infarction on the 
day after testing; 3 h of atrial fibrillation beginning after the 
investigator twice restarted arbutamine after the delivery sys- 
tem terminated the infusion because of failure of heart rate to 
continue to increase; and ventricular tachycardia/fibrillation 
(again converted by direct current shock) beginning after the 
investigator restarted arbutamine when the delivery system 
terminated the infusion because of a decrease in heart rate 
(the delivery device recognizes failure of heart rate to increase 
or a decrease inheart rate as drug "saturation" and terminates 
the infusion). Four of these patients had significant multivessel 
disease (the patient with atrial fibrillation had single-vessel 
disease), and all five patients recovered uneventfully. 
Other reactions associated with arbutamine administration 
in the sensitivity group, in addition to those mentioned previ- 
ously, were most commonly those associated with cat- 
echolamines: flushing phenomena (15%), tremor (12%), head- 
ache (12%), heart rate and rhythm disorders (7%), dizziness 
(5%) and decreased blood pressure (5%). 
Discussion 
The results of the present study show that arbutamine is
superior to exercise testing for detection of ischemia using ST 
segment change or angina, or angina alone, and similar to 
Table 7. Demographics of Patients in the Low Risk Group and 
Occurrence of Ischemic Changes 










Angina on arbutamine 
ST segment change ->1 mm with arbutamine 
Angina or ST segment change ->1 mm with 
arbutamine 










42.5 + 11.9 
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exercise for the ECG end point of ST segment change alone. 
There are several possible reasons for the superiority of 
arbutamine over exercise. 
Hemodynamic results. In the present study, arbutamine 
produced a mean blood pressure change less than that for 
exercise and heart rate changes imilar to those for exercise, 
although the heart rate targets were slightly different for each. 
The arbutamine effect usually continued briefly after termina- 
tion of the infusion. 
Heart rate is possibly the most important determinant of
myocardial ischemia (11) and has been confirmed in studies 
using dobutamine to detect myocardial ischemia (12,13). In- 
creasing heart rate increases contractility through the force- 
frequency relation, especially with exercise (14). A portion of 
the heart rate effect may also involve impairment of coronary 
perfusion because coronary perfusion is primarily a diastolic 
event, and increasing heart rate is associated primarily with a 
loss of diastolic time. In addition to the effects on energy 
demands related to increased contractility, increasing heart 
rate reduces ubendocardial b ood flow (11), thus affecting 
energy supply. 
Other contributors to increased myocardial energy de- 
mands include blood pressure and inotropy. Systolic blood 
pressure, and therefore rate-pressure product, increased to a 
greater extent with exercise than arbutamine. Although all 
hemodynamic variables tracked together with exercise, there 
was a dissociation between diastolic blood pressure response 
and heart rate/systolic blood pressure with arbutamine. Thus, 
the major determinants of energy consumption peaked long 
before one of the major determinants of coronary flow-- 
diastolic blood pressure during arbutamine infusion. In fact, 
mean diastolic blood pressure was at a minimum at 11.8 _+ 
11.2 min, a time close to that of maximal energy demands. The 
actual contribution of increased inotropy to the production of 
myocardial ischemia is unknown with regard to either arbu- 
tamine or exercise but could play a role in enhancing ischemia 
with arbutaminc. 
One possibility for the effectiveness of arbutamine may be 
its specific hemodynamic properties, causing an increase in 
heart rate, arterial pressure and inotropy. Arbutamine mani- 
fests these properties inthe general order of their importance. 
Another possibility may be the temporal discrepancy among 
the determinants of energy supply and demand noted earlier. 
A third possibility may be the delivery system, which provides 
a constant rate of heart rate increase in addition to providing 
safeguards. This difference in "exercise conditions"--the 
steady increase in heart rate and blood pressure with arbu- 
tamine as opposed to the incremental increase with exercise 
testing--may affect he ischemic threshold (15). 
Sensitivity. The sensitivity of exercise in the present study 
was similar to that found in a summary of 33 studies involving 
7,501 patients (16). This similarity suggests that our patients 
are comparable to those in other studies. However, in the 
present study, arbutamine was significantly more sensitive than 
exercise in detecting myocardial ischemia on the basis of 
angina lone or angina or ST segment change. The difference 
in sensitivity between arbutamine and exercise for the ST 
segment end point was only three percentage points (47% vs. 
44%, respectively), which was not statistically significant, The 
power of the study to detect a difference in 10 absolute 
percentage points in sensitivity between the two tests for the 
ST segment end point was 82%. Thus, the sample size was 
sufficient to detect aclinically meaningful difference, although 
for ST segment change, one was not observed. 
In the low risk group, 80% of patients receiving arbutamine 
had no evidence of significant myocardial ischemia under both 
clinical and ECG criteria. However, the two groups evaluated 
in the present study represent different patient groups and 
cannot be used to describe sensitivity and specificity in a 
complementary manner. The low risk group had some risk for 
coronary artery disease and was referred for evaluation of 
possible coronary artery disease because of symptomatic chest 
pain or risk factors. The sensitivity group included amixture of 
patients with either known coronary disease or a high pretest 
probability of disease. 
The absence of angina in the low risk group makes it clear 
that angina is not a nonspecific effect but rather a significant 
indicator of ischemia, as demonstrated in the present study and 
in other studies with dobutamine (17). It is also known that he 
ischemic threshold varies under different exercise conditions 
and may be expressed by angina or ST segment changes (15). 
The importance of angina is demonstrated byits association 
with a significantly worse prognosis than ST segment changes 
alone (18). 
The present study was designed to go beyond first detection 
of ischemia to an end point of 0.2-mV ST segment deviation to 
ensure a reviewable nd point at 0.1-mV ST segment change. 
Some of the adverse ffects may have occurred after the test 
would have been discontinued in clinical practice. Some ad- 
verse effects were associated with restarting arbutamine after 
built-in safety mechanisms had stopped the infusion. Except 
for certain technical difficulties that could occur, this action 
may be clinically inappropriate. Only one significant adverse 
effect--a readily reversed episode of ventricular tachycardia/ 
fibrillation--had a clear relation to arbutamine infusion as it 
should be given in clinical practice. This event occurred in a 
patient with severe three-vessel coronary disease with three 
prior myocardial infarctions. Aside from this adverse ffect, 
most others noted were minor and were commonly associated 
with catecholamines. 
Comparison with studies using dobutamine. Many studies 
(17,19-23) have compared exercise with dobutamine infusion 
and found less heart rate and rate-pressure product response 
with dobutamine than with exercise. The maximal rate- 
pressure product produced with arbutamine orexercise in the 
present study was similar to that found previously with exercise 
but somewhat greater than that attributed todobutamine when 
dobutamine and exercise were compared (20,21). 
In general, dobutamine in conjunction with ECG and 
clinical end points has been less sensitive than exercise in 
detecting myocardial ischemia (20). There are several reasons 
why arbutamine may be superior to dobutamine in producing 
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myocardial ischemia. Arbutamine appears to possess greater 
heart rate- and blood pressure-increasing properties than 
dobutamine. In addition, dobutamine did not increase mean 
blood pressure in studies (17) in which this value was reported, 
whereas mean blood pressure does increase with arbutamine. 
This finding may reflect a more conservative clinical use of 
dobutamine for diagnostic testing, whereas arbutamine dosing 
was controlled by the delivery device. In addition, dobutamine 
was designed primarily to increase contractility (24), but this 
effect appears to contribute minimally to the coronary artery 
flow limitation associated with exercise (12). Although arbu- 
tamine was shown to be more sensitive than exercise in the 
present study, only a direct comparison with dobutamine can 
determine whether arbutamine, combined with a closed-loop 
administration system, is diagnostically superior to dobut- 
amine. 
In the low risk group, the nonischemic response found for 
arbutamine (80%) is similar to that for dobutamine in con- 
junction with ECG and clinical indicators in other studies 
(17,20). The adverse effects found for arbutamine are also 
similar to those reported for dobutamine (25) despite the 
similar heart rate and greater blood pressure change produced 
by arbutamine. 
Conclusions. A test may be useful for identification of a 
general disease process or, alternatively, for indicating the 
need for further action. The high sensitivity of arbutamine in 
two- and three-vessel disease may be important in screening 
those patients in need of further intervention. In the case of 
one-vessel disease without severe signs or symptoms, the need 
for further action (other than noninterventional preventive 
treatment) is not likely (26,27). Thus, the identification of 
one-vessel coronary disease in asymptomatic or minimally 
symptomatic subjects is of less benefit han the identification of 
two- or three-vessel disease (127). As a second-level screening 
tool after the risk factors of history, physical examination and 
basic laboratory findings have been considered, arbutamine 
infusion using the closed-loop device may be effective because 
of its ease of use, ease of transport, requirement for less 
physical space and applicability for those who cannot exercise 
adequately. It appears to be significantly more sensitive than 
the most common screening tool now used clinically--the 
standard exercise readmill test. 
Appendix 1 
The arbutamine infusion device is a proprietary computer- 
controlled, heart rate feedback (closed-loop) delivery system; that is, 
the infusion rate is adjusted according to heart rate data feedback. The 
system is designed to infuse arbutamine according to the rate of heart 
rate increase (heart rote slope, range 4 to 12 beats/min per min) up to 
the maximal heart rate (heart rate target) determined by the physician 
before the test. The system automatically monitors heart rate at 5-s 
and blood pressure at 2-rain intervals throughout the infusion period, 
and these intervals can be changed. The system has built-in audible and 
visual alerts and alarms that are activated in response to changes in 
heart rate and blood pressure and other clinical and system problems. 
The system is capable of stopping the infusion if certain limits are 
exceeded. These features are designed to identify potential problems, 
such as rapid changes in heart rate or a paradoxic decrease in blood 
pressure. 
Appendix 2 
Participating Investigators and Clinical Sites for the 
International Arbutamine Study Group 
C. Appleton, VA Medical Center, Tucson, AZ; S. Baker, Stanislaus Cardiology, 
Modesto, CA; T. Bateman, Cardiovascular Consultants, Inc., Kansas City, MO; 
P. Bear, Iowa Heart Center, Des Moines, /A; G. Beller, University of Virginia 
Health Sciences Center, Charlottesville, VA; E. H. Botvinick, University California, 
San Francisco, San Francisco, CA; N. Campbell, Royal Victoria Hospital, Belfast, 
Northern Ireland; M. Cerqueira, Veterans Administration Medical Center, Seattle, 
14~4; J. Chambers, Guys Hospital, London, U./~; K. Chan, University of Ottawa 
Heart Institute, Ottawa, Canada; F. Chaudhry, Northwestern U iversity, Chicago, 
IL : J. Cohen, l,~l Medical Center, East Orange, NJ; F. Conte, David Grant United 
States Air Force Medical Center, Travis AFB, CA; M. Crawford, VA Medical 
Center, Albuquerque, NM; L. Crouse, Mid-American Cardiology Associates, P.C, 
Kansas Ci~£, MO; P. Daley, Fort Wayne Cardiology, Inc., Fort Wayne, IN; 
H. Dargie, S. Hillis, Gardiner Institute, Glasgow, U.K.; J. Davies, Royal Gwent 
Hospital Gwent, Wales, l~K.; P. Decoodt, Brugmann Hospital, Brussels, Belgium; 
C. Dennis, Deborah Heart and Lung Center, Browns Mills, NJ; M. DeWood, Heart 
Institute of Spokane, Spokane, WA; P. Douglas, Beth Israel Hospital, Boston, MA; 
L. Edwards, Edward Hines, Jr. VA Hospital, Hines, IL; H. Emanuelsson, 
Sahlgrenska Hospital, Gothenburg, Sweden; I. Findlay, Royal Alexandra Hospital, 
Glasgow, U.K; E. Foster, University of California, San Francisco, San Francisco, 
CA: A. Garvey, Providence Medical Center, Portland, OR; L. Ginzton, Harbor 
UCLA Medical Center, Torrance, CA; A. Gradman, The Western Pennsylvania 
Hospital. Pittsburgh. PA; R. Greenbaum, Edgware General Hospital, 
Middlesex, U.K.; P. Hanrath, Medizinisehe Klinik, Aachen, Germany; G. Heller, 
Memorial Hospital, Pawtucket, R/; R. C. Hendel, Northwestern U iversity, Chi- 
cago, 1L; S. ttillis, Gardiner Institute, Glasgow, U.K.; A. Iskandrian, Philadelphia 
Heart Institute, Philadelphia, PA; W. Jaarsma, St. Antonius Hospital, Nieuwegein, 
The Netherlands; A. Katz, Miriam Hospital, Providence, R/; B. Khandheria, Mayo 
Clime, Rochester, MN; H. Kiat, Cedars Sinai Medical Center, Los Angeles, CA; 
W. P. Klinke, Royal Alexandra Hospital, Edmonton. Alberta, Canada; W. Kostuk, 
University Hospital, London, Ontario, Canada; J. A. Leppo, University of Massa- 
chusetts Medical Center, Worcester, MA; H. Miller, Wake Forest University, 
Wimton-Salem, NC; S. M. Mohiuddin, Creighton University, Omaha, NE; 
B. Moll Aurora Denver Cardiology, Aurora, CO; J. Nemec, Creighton University 
Medical Center. Omaha, NE; D. P. Nichols, Royal Victoria Hospital, Belfast, 
Northern Ireland; C. Ostromecki, Deborah Heart and Lung Center, Browns Mills, 
NJ; E. J. Perrins, The General Infirmary at Leeds, Leeds, U.K; L. Pierard, 
Universite de Liege, Liege, Belgium; C. Reid, University of California, Irvine, 
Orange. CA; M. Robitaille, H6pital Laval, Sainte-Foy, Quebec, Canada; T. Ruddy, 
Universio, of Ottawa Heart Institute, Ottawa, Ontario, Canada; R. Schroeder, 
Klinikum Steglitz, Berlin, Germany'; D. Segar, Krannert Institute of Cardiology, 
lmlianapolis, IN; J. Sklar, Cardiology Associates of Marin and San Francisco, 
Larkspur CA; M. Slayton, Virginia Polytechnic Institute, Blacksburg, VA; 
J. Stephens, Oldchurch Hospital Essex, U.K.; G. Sutherland, Western General 
Hospital, Edinburg, U.K; L. B. Tan, Killingbeck Hospttal, Leeds, U.K.; U. Thadani, 
University of Oklahoma Health Sciences Center, Oklahoma City, OK; J. Udelson, 
New England Medical Center Hospital, Boston, MA; C. Vasey, Asheville Cardiology 
Associates, P.A.. Asheville, NC; B. G. Villegas, University of Massachusetts Medical 
Center, Worcester, MA; H. VonBibra, Technische, Universitat, Munchen, Germany; 
R. Wainwright, The Brook Hospital London, England; D. Whang, Fort Wayne 
Cardiology, Fort Wayne, IN', P. M. Wolfson, Olympia Fields Osteopathic Hospital 
& Medical Ctr. O~mpia Fields, IL. 
The following investigators and sites conducted independent analyses ofthe 
respective elficacy data: Thallium-20l single-photon emission computed torah- 
graphic data: Daniel S. Berman and Kenneth Van Train, Cedars-Sinai Medical 
Center Lo~s Angeles, CA. Electrocardiographic data: Victor F. Froelicher, MD, 
Stan]brd University Cardiology Dept., Pain Alto, CA. Angiographic data: Mark R. 
Starling, MD, and David W. M. Muller, MBBS, University of Michigan, Ann 
Arbor MI. Echocardiographie data: William Armstrong and David Bach, 
University Of Michigan, Ann Arbor, MI. 
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